MARIJUANA PHARMACOTHERAPIES: CONTROLLED CLINICAL TRIALS

大麻药物治疗：对照临床试验

• 批准号: 6515756
• 负责人: DAVID J MCDOWELL
• 金额: $ 37.82万
• 依托单位: NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2004-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6515756
• 关键词: antidepressants; bupropion; clinical research; clinical trials; drug abuse chemotherapy; drug screening /evaluation; drug withdrawal; human subject; human therapy evaluation; marijuana abuse; outcomes research; piperazines

DESCRIPTION: (Applicant's Abstract) Cannabis preparations are the most commonly used illicit substances in the United States. In recent years, rates of marijuana use and, in turn, dependence have been rising, especially among younger people. Heavy and chronic use of marijuana carries with it substantial morbidity. In the years to come, cannabis dependence will likely become an even more severe and prevalent health problem. Compared to other substances of abuse, the treatment of heavy and chronic marijuana use (dependence) has received comparatively little investigation. There are very few controlled treatment trials for cannabis dependence. Recent animal and human laboratory studies have characterized substantial withdrawal symptoms associated with the abrupt cessation of marijuana. These symptoms are characterized by a range of effects that include anxiety, irritability, somatic complaints, and difficulty sleeping. The symptoms associated with marijuana withdrawal resemble both depression and nicotine withdrawal, suggesting the utility of a pharmacological intervention. We propose a carefully constructed double-blind placebo-controlled trial testing two agents, bupropion and nefazodone, in the context of psychosocial intervention. We hypothesize that reducing withdrawal symptoms will result in greater retention in treatment and lead to higher rates of abstinence in treatment seeking marijuana users.

描述：（申请人摘要）